Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

Moore, who like the EMTs was decked out in personal protective equipment, kept out of their way as he tried to respectfully take photos of the life-threatening situation. Unfortunately ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results ...

Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

ESK-001, a tyrosine kinase 2 inhibitor, may be a promising new oral treatment for plaque psoriasis. Patients taking ESK-001 twice daily maintained skin clearance up to a year. ORLANDO — Patients ...

announced today that the data of the novel TYK2 inhibitor ICP-488 developed by the Company for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 ...

of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. According to the company, the data demonstrated that patients receiving 40 mg twice ...